Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 13

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 13
---
 |

| ● | no other representations; or |

| ● | ownership of stock. |

No party’s representations, warranties or pre-Closing covenants will survive the Closing, and no party has any post-Closing indemnification obligations; provided, however, that NLS will hold, and will cause its representatives to hold, in confidence all documents and information furnished to it by or on behalf of Kadimastem pursuant to the Merger Agreement. The covenants and agreements of the parties shall not survive the Closing, except those covenants and agreements to be performed after the Closing which covenants and agreements shall survive until fully performed. Each party agreed in the Merger Agreement to use its commercially reasonable efforts to effect the Closing. The Merger Agreement also contains certain customary covenants by each of the parties during the Interim Period (as defined in the Merger Agreement), including (1) the provision of access to such party’s properties, books, other information and personnel; (2) notifications of certain breaches, consent requirements or other matters; (3) commercially reasonable efforts to consummate the Closing and obtain third party and regulatory approvals; (4) tax matters and tax rulings; (5) further assurances that the parties shall further cooperate with each other to consummate the transactions contemplated therein; and (6) public announcements concerning the Merger Agreement and the transactions contemplated therein. In addition, the Merger Agreement contains covenants by NLS with respect to the performance of Merger Sub during the Interim Period and obtaining necessary Israeli Securities Authority Approvals.

<div align='center'>5</div>

Pursuant to the Merger Agreement,
except with the prior written consent of from the other party, NLS and Kadimastem will and will cause each of their subsidiaries to: (i)
not take any action that would or would reasonably be expected to prevent, materially impair or materially delay the ability of NLS, Kadimastem
or Merger Sub to consummate the transactions contemplated by the Merger Agreement, (ii) conduct its operations in all material respects
in the ordinary and usual course of business consistent with past practice, and (iii) use its reasonable best efforts to preserve intact
its corporate existence. Each of NLS and Kadimastem also agreed that it will not, without a prior written consent of the other party,
(i) amend or authorize any amendments to the terms of any of its outstanding securities or its governing or organizational documents,
or to the governing or organizational documents